These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Not reported 2012-004463-41 - 2015-12-02 due-trials
Ongoing 2014-004698-17 A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic bre... not-yet-due
Ongoing 2015-003892-31 A multicenter, international, non-controlled, phase II trial to identify the molecular mechanisms of resistance and sensitivity to palbociclib re-challenge upon progression to a palbociclib combinatio... not-yet-due
Ongoing 2015-004828-66 A phase IIa clinical trial to evaluate the safety and efficacy of osirmertinib (AZD9291) in first-line patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer an... not-yet-due
Ongoing 2016-001888-36 A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide bes... not-yet-due
Ongoing 2016-002676-27 Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. The PHERGain study not-yet-due
Ongoing 2016-002689-30 Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER2-negative breast cancer not-yet-due
Ongoing 2016-002892-80 A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC) patients with homologous recombination deficiency treated with OLAparib single agent (NOBROLA study) not-yet-due
Ongoing 2016-004513-27 A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes not-yet-due
Ongoing 2018-001702-28 Neoadjuvant Letrozole and Palbociclib in patients with Stage II-IIIb breast cancer, HR (+) / HER2 (-) phenotype and Intermediate (18-25) or High (>25) Recurrence-Score by Oncotype-DX; analysis of RS a... not-yet-due